Uptool | $6,000,000 | (Feb 10, 2026)
BotGauge AI | $2,000,000 | (Feb 10, 2026)
Linkup(US) | $10,000,000 | (Feb 10, 2026)
Certified by Founder
Lodge
ErVimmune
start up
- 21/01/2026
- Series A
- $19,917,795
Targeting shared unconventional tumor antigens in cancer immunotherapy
- Industry Biotechnology Research
- Website https://ervimmune.com/
- LinkedIn https://www.linkedin.com/company/ervimmune/
Related People
Stéphane DEPILFounder
France -
Onco-hematologist at Centre Léon Bérard and leader of the team "Antigen presentation, T cell and Cancer" at Cancer Research Center of Lyon. Over 20 years of experience in oncology research and drug development both in academia and pharma/biotech companies as former SVP R&D and CMO at Cellectis, CEO at Netris Pharma and Head of OncologyR&D at Servier.Founder and board member of ErVimmune, a biotech company developing cancer vaccines and T cell therapies targeting non-conventional tumor epitopes.
Phylo | $13,500,000 | (Feb 10, 2026)
pHathom Technologies, Inc | $4,000,000 | (Feb 10, 2026)
Modveon | $10,000,000 | (Feb 10, 2026)
Bound | $24,500,000 | (Feb 10, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Advance | $8,550,000 | (Feb 6, 2026)